Navigation Links
Arsenic early in treatment improves survival for leukemia patients
Date:11/11/2010

WINSTON-SALEM, N.C. Thursday, Nov. 11, 2010 Arsenic, a toxic compound with a reputation as a good tool for committing homicide, has a significant positive effect on the survival of patients with acute promyelocytic leukemia (APL), when administered after standard initial treatment, according to a new, multi-center study led by a researcher at Wake Forest University Baptist Medical Center.

While arsenic trioxide (As2O3) is known by clinicians to be a highly effective treatment for patients with relapsed APL, its benefit earlier in treatment, after first remission, has remained unknownuntil now.

Researchers with the Cancer and Leukemia Group B, a group of cancer and leukemia researchers funded by the National Cancer Institute, led a study to determine if, by administering arsenic trioxide earlier after a patient has finished standard initial treatment and reached first remission they could improve survival rates. The results were dramatic.

"Patients with APL can achieve remission with standard treatment (chemotherapy plus ATRA, an oral vitamin A-based compound), but it often comes back," said Bayard L. Powell, M.D., a professor of hematology and oncology at Wake Forest Baptist, principal investigator and lead author on the study. "Arsenic trioxide is then used to get them back into remission, often followed by a bone marrow transplant to try to cure the patient. For this study, we used arsenic as an early "consolidation therapy" after the initial standard treatment to essentially, as one of our first patients described, 'seal the deal' the first time around. Not only did the leukemia rarely return in the patients who received the arsenic, those patients also lived longer."

The findings appear in the November 11 issue of Blood.

APL accounts for about 10 to 15 percent of acute myeloid leukemia cases and presents most frequently in young adults. It is associated with a very high risk of severe bleeding com
'/>"/>

Contact: Bonnie Davis
bdavis@wfubmc.edu
336-716-4977
Wake Forest University Baptist Medical Center
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. Arsenic and old toenails
2. Montana State team finds Yellowstone alga that detoxifies arsenic
3. Stanford scientists find new solutions for the arsenic-poisoning crisis in Asia
4. Geologists studying groundwater arsenic levels in India empower Bengali women, children
5. Lehigh University professor receives Astellas Award for arsenic groundwater remediation efforts
6. Arsenic hyperaccumulating ferns: How do they survive?
7. Ferns evolution gives arsenic tolerance that may clean toxic land
8. New arsenic nanoparticle blocks aggressive breast cancer
9. Arsenic in field runoff linked to poultry litter
10. Scientists solve mystery of arsenic compound
11. Stevens strengthens Dominican Republics Early Warning System for Inundations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Dec. 16, 2014  Automation is fundamentally ... more evident than at international borders. Over the ... scanners have allowed veteran travelers to self process ... Control (APC) Kiosks at an increasing number of ... According to Maxine Most ...
(Date:12/11/2014)... , Dec. 10, 2014  Data Sciences International ... has released a new series of digital telemetry ... toxicology researchers. M series, part of the PhysioTel™ ... the best possible physiologic data when incorporating functional ... functional endpoints to toxicology studies has evolved from ...
(Date:12/10/2014)... Research and Markets ( http://www.researchandmarkets.com/research/xclcvw/biometrics_market ... "Biometrics Market in Japan 2014-2018" report to ... The integration of biometrics and ... and upgradation of the driver,s license is one ... Besides the aforementioned projects, biometrics is being used ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2New telemetry implants expected to change how large animal toxicology studies are conducted 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2
... hypothesis, the idea that predators can keep packs of prey ... the chance disease will wipe out the whole herd, but ... more susceptible to other predators or even parasites? Biologists at ... animal whose defenses against a predator make it a good ...
... movements of an entire sub-population of marine turtle for ... tracking we can closely observe the day-to-day lives of ... conservation efforts. Writing in the journal ... Exeter PhD student Dr Lucy Hawkes (now at Bangor ...
... has brought scientists one step closer to developing treatments ... prevent the sexual transmission of HIV. ... that target specific proteins associated with Alzheimer,s disease and ... elongated chains of interlocking proteins that play a key ...
Cached Biology News:Scientists uncover an unhealthy herds hypothesis 2Exeter study reveals US turtles' movements 2Breaking the chain: 'Molecular cap' blocks processes that lead to Alzheimer's, HIV 2Breaking the chain: 'Molecular cap' blocks processes that lead to Alzheimer's, HIV 3Breaking the chain: 'Molecular cap' blocks processes that lead to Alzheimer's, HIV 4
(Date:12/22/2014)... HILL, N.C. , Dec. 22, 2014 /PRNewswire/ ... today announced that it has signed a letter ... company that has developed and patented a nanotechnology-based ... medical diagnostics products that enable rapid on-site collection ... alcohol use/abuse and health issues in an immediate, ...
(Date:12/22/2014)... MISSION VIEJO, Calif. , Dec. 22, 2014 /PRNewswire/ ... announce that CoPatient, an online medical bill review and ... newest offering in the FREE WellCard Savings discount health ... a medical bill that was more than they expected ... help members reduce health care costs, WellCard Savings is ...
(Date:12/22/2014)... Illinois (PRWEB) December 22, 2014 ITRA ... tenants and occupiers of commercial real estate, has further ... new offices in Perth and Brisbane, Western Australia, reports ... of directors. , ITRA Global / ACORPP (Australian ... totally independent consultancy company providing property services to a ...
(Date:12/19/2014)... OR and Hershey, PA (PRWEB) December 19, 2014 ... Pink: BJCT), a leading developer and manufacturer of ... entered into an agreement with Immunomic Therapeutics, Inc. ... Biojector®-2000 needle-free injection device with its LAMP™ vaccine ... an option for an exclusive Worldwide license to ...
Breaking Biology Technology:ALNE Announces Intention To Acquire BioTechPharma 2WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3
... /PRNewswire/ -- Campbell Alliance, the leading management consulting ... that it has launched a new practice area focused on ... the Medical Affairs practice enables the firm to specifically target ... , "Our firm has done work in the area ...
... , OSLO, Norway, June 17 ... Drug Also Shown to Improve Remission Rates and,Reduce Short-Term ... Clavis Pharma ASA (OSE: CLAVIS) today announces positive ... investigational cancer drug, elacytarabine,(CP-4055), in patients with late-stage acute ...
... and Validation of New Biomarker Panels , ... Incorporated (RBM), the world,s leading multiplexed biomarker testing ... comprehensive collection of quantitative immunoassays for use in ... diagnostic development. The new service, DiscoveryMAP(TM) v 1.0, ...
Cached Biology Technology:Campbell Alliance Launches New Practice Area Focused on Medical Affairs 2Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 2Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 3Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 4Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 5Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 6Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 7Rules-Based Medicine, Inc. Launches DiscoveryMAP(TM) Service for Drug and Diagnostic Development 2Rules-Based Medicine, Inc. Launches DiscoveryMAP(TM) Service for Drug and Diagnostic Development 3
Goat polyclonal to SPFH2 ( Abpromise for all tested applications). Antigen: Synthetic peptide: EDEPLETATKEN, corresponding to C terminal amino acids 328-339 of Human SPFH2 Entrez Gene ID: 11...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
alpha/beta-Tubulin Antibody Ship: Hot Store: -20 C...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
Biology Products: